\babel@toc {english}{}\relax 
\contentsline {section}{\numberline {1}Executive Summary}{2}{section.1}%
\contentsline {section}{\numberline {2}Multiple Myeloma \& Proteasome Biology}{2}{section.2}%
\contentsline {subsection}{\numberline {2.1}Multiple Myeloma Pathophysiology}{2}{subsection.2.1}%
\contentsline {subsection}{\numberline {2.2}The Proteasome System}{2}{subsection.2.2}%
\contentsline {subsection}{\numberline {2.3}Current MM Therapeutic Landscape}{2}{subsection.2.3}%
\contentsline {section}{\numberline {3}Human 20S Proteasome Structure}{2}{section.3}%
\contentsline {subsection}{\numberline {3.1}Overall Architecture}{2}{subsection.3.1}%
\contentsline {subsection}{\numberline {3.2}Crystal Structure Properties}{3}{subsection.3.2}%
\contentsline {subsection}{\numberline {3.3}Proteasome Subunit Composition}{3}{subsection.3.3}%
\contentsline {subsection}{\numberline {3.4}Molecular Structure Visualization}{4}{subsection.3.4}%
\contentsline {section}{\numberline {4}Bortezomib Binding Mechanism}{4}{section.4}%
\contentsline {subsection}{\numberline {4.1}Molecular Recognition and Binding}{4}{subsection.4.1}%
\contentsline {subsection}{\numberline {4.2}Active Site Architecture}{5}{subsection.4.2}%
\contentsline {section}{\numberline {5}Drug Resistance Analysis}{5}{section.5}%
\contentsline {subsection}{\numberline {5.1}Clinical Resistance Patterns}{5}{subsection.5.1}%
\contentsline {subsection}{\numberline {5.2}Mutation Analysis}{5}{subsection.5.2}%
\contentsline {subsection}{\numberline {5.3}Resistance Mechanisms Detail}{5}{subsection.5.3}%
\contentsline {section}{\numberline {6}Mutation Analysis}{6}{section.6}%
\contentsline {section}{\numberline {7}Therapeutic Compounds Analysis}{6}{section.7}%
\contentsline {subsection}{\numberline {7.1}Bortezomib (Velcade\textsuperscript {\textregistered })}{6}{subsection.7.1}%
\contentsline {subsubsection}{\numberline {7.1.1}Drug Properties}{6}{subsubsection.7.1.1}%
\contentsline {subsubsection}{\numberline {7.1.2}Clinical Efficacy}{6}{subsubsection.7.1.2}%
\contentsline {subsubsection}{\numberline {7.1.3}Pharmacokinetics}{7}{subsubsection.7.1.3}%
\contentsline {subsection}{\numberline {7.2}Next-Generation Proteasome Inhibitors}{7}{subsection.7.2}%
\contentsline {subsection}{\numberline {7.3}Comparison with Related Structures}{7}{subsection.7.3}%
\contentsline {section}{\numberline {8}Structure-Activity Relationships (SAR)}{7}{section.8}%
\contentsline {subsection}{\numberline {8.1}Boronic Acid Pharmacophore}{7}{subsection.8.1}%
\contentsline {subsection}{\numberline {8.2}Peptide Recognition Elements}{8}{subsection.8.2}%
\contentsline {subsection}{\numberline {8.3}Design Principles for Next-Generation Inhibitors}{8}{subsection.8.3}%
\contentsline {section}{\numberline {9}Pharmacokinetic \& Safety Profile}{8}{section.9}%
\contentsline {subsection}{\numberline {9.1}ADMET Properties}{8}{subsection.9.1}%
\contentsline {subsection}{\numberline {9.2}Adverse Event Profile}{8}{subsection.9.2}%
\contentsline {subsection}{\numberline {9.3}Dose Optimization Strategies}{9}{subsection.9.3}%
\contentsline {section}{\numberline {10}Clinical Implications}{9}{section.10}%
\contentsline {subsection}{\numberline {10.1}Current Treatment Paradigms}{9}{subsection.10.1}%
\contentsline {subsubsection}{\numberline {10.1.1}Newly Diagnosed Multiple Myeloma}{9}{subsubsection.10.1.1}%
\contentsline {subsubsection}{\numberline {10.1.2}Relapsed/Refractory Multiple Myeloma}{9}{subsubsection.10.1.2}%
\contentsline {subsection}{\numberline {10.2}Biomarker-Guided Therapy}{9}{subsection.10.2}%
\contentsline {subsubsection}{\numberline {10.2.1}Prognostic Biomarkers}{9}{subsubsection.10.2.1}%
\contentsline {subsubsection}{\numberline {10.2.2}Predictive Biomarkers}{9}{subsubsection.10.2.2}%
\contentsline {subsection}{\numberline {10.3}Combination Therapy Strategies}{10}{subsection.10.3}%
\contentsline {subsubsection}{\numberline {10.3.1}Synergistic Mechanisms}{10}{subsubsection.10.3.1}%
\contentsline {subsubsection}{\numberline {10.3.2}Emerging Combination Approaches}{10}{subsubsection.10.3.2}%
\contentsline {subsection}{\numberline {10.4}Resistance Management}{10}{subsection.10.4}%
\contentsline {subsubsection}{\numberline {10.4.1}Sequential Therapy Approach}{10}{subsubsection.10.4.1}%
\contentsline {subsubsection}{\numberline {10.4.2}Mechanism-Based Selection}{10}{subsubsection.10.4.2}%
\contentsline {subsection}{\numberline {10.5}Future Therapeutic Directions}{10}{subsection.10.5}%
\contentsline {subsubsection}{\numberline {10.5.1}Next-Generation Proteasome Inhibitors}{10}{subsubsection.10.5.1}%
\contentsline {subsubsection}{\numberline {10.5.2}Precision Medicine Approaches}{11}{subsubsection.10.5.2}%
\contentsline {subsubsection}{\numberline {10.5.3}Combination Innovation}{11}{subsubsection.10.5.3}%
\contentsline {section}{\numberline {11}Computational Analysis \& Quality Assessment}{11}{section.11}%
\contentsline {section}{\numberline {12}Future Research Directions}{11}{section.12}%
\contentsline {subsection}{\numberline {12.1}Structural Biology Priorities}{11}{subsection.12.1}%
\contentsline {subsection}{\numberline {12.2}Drug Discovery Applications}{12}{subsection.12.2}%
\contentsline {subsection}{\numberline {12.3}Clinical Translation}{12}{subsection.12.3}%
\contentsline {section}{\numberline {13}Conclusions}{12}{section.13}%
\contentsline {subsection}{\numberline {13.1}Key Scientific Findings}{12}{subsection.13.1}%
\contentsline {subsection}{\numberline {13.2}Clinical Implications}{12}{subsection.13.2}%
\contentsline {subsection}{\numberline {13.3}Future Opportunities}{13}{subsection.13.3}%
\contentsline {section}{\numberline {14}Supplementary Information}{13}{section.14}%
\contentsline {subsection}{\numberline {14.1}Data Availability}{13}{subsection.14.1}%
\contentsline {subsection}{\numberline {14.2}Software and Tools}{13}{subsection.14.2}%
\contentsline {section}{\numberline {15}References}{14}{section.15}%
\contentsline {section}{\numberline {A}Technical Specifications}{15}{appendix.A}%
\contentsline {subsection}{\numberline {A.1}Computational Environment}{15}{subsection.A.1}%
\contentsline {subsection}{\numberline {A.2}Analysis Parameters}{15}{subsection.A.2}%
\contentsline {subsection}{\numberline {A.3}File Formats}{15}{subsection.A.3}%
\contentsline {section}{\numberline {B}Mutation Database Cross-Reference}{15}{appendix.B}%
\contentsline {subsection}{\numberline {B.1}COSMIC Database Integration}{15}{subsection.B.1}%
\contentsline {subsection}{\numberline {B.2}ClinVar Integration}{15}{subsection.B.2}%
\contentsline {subsection}{\numberline {B.3}PharmGKB Integration}{16}{subsection.B.3}%
